Positive data from a Phase II trial with the antibody-drug conjugate (ADC) glembatumumab vedotin (CDX-011) in patients with metastatic, triple-negative breast cancers (TNBC) that overexpress glycoprotein non-metastatic melanoma protein (GPNMB) have led Celldex Therapeutics Inc. to fire up a pivotal study called METRIC that could lead to accelerated approval.